表紙
市場調查報告書

子宮頸癌的診斷藥和治療藥市場 - 成長,趨勢,預測(2019年∼2024年)

Cervical Cancer Diagnostics and Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 353906
出版日期 內容資訊 英文 116 Pages
商品交期: 2-3個工作天內
價格
Back to Top
子宮頸癌的診斷藥和治療藥市場 - 成長,趨勢,預測(2019年∼2024年) Cervical Cancer Diagnostics and Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年02月01日內容資訊: 英文 116 Pages
簡介

全球子宮頸癌診斷及治療藥市場,由於政府對預防採取的措施,及罹患率的上升,早期診斷的關注高漲,主要企業對子宮頸癌的強力的研究開發等,促進成長。

本報告提供子宮頸癌診斷及治療藥的世界市場調查,市場概要,各診斷檢驗、治療藥、終端用戶的市場規模的變化與預測,市場成長要素及阻礙因素分析,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

  • 調查成果
  • 前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 政府對預防子宮頸癌的配合措施
    • 子宮頸癌的罹患率上升
    • 早期診斷的關注高漲
    • 子宮頸癌的診斷及治療藥的研究開發
  • 市場阻礙因素
    • 面臨定期體檢的引進的經濟課題
    • 癌症治療的成本高
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第5章 市場區隔

  • 診斷檢查別
    • 子宮頸抹片檢查
    • 人類乳突病毒(HPV)檢驗
    • 陰道鏡檢查
    • 切片檢查、子宮頸內刮宮術
    • 其他
  • 各治療藥物
    • Avastin (Bevacizumab)
    • Blenoxane (Bleomycin)
    • Hycamtin (Topotecan Hydrochloride)
    • Gemcitabine-Cisplatin
    • 疫苗
    • 其他
  • 各終端用戶
    • 醫院
    • 專門診所
    • 癌症/放射線治療中心
    • 診斷中心
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Abbott Laboratories
    • Bristol-Meyrs Squibb Company
    • GlaxoSmithKline PLC
    • Merck & Co. Inc.
    • Pfizer Inc.
    • Qiagen NV
    • Advaxis Inc.
    • Becton, Dickinson and Company
    • F. Hoffmann-La Roche Ltd

第7章 市場機會及未來趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 56560

Market Overview

The factors propelling the growth of the cervical cancer diagnostics and therapeutics market are favorable government initiatives toward cervical cancer prevention, the growing prevalence of cervical cancer, an increase of awareness regarding early diagnosis, and strong R&D from key players for cervical cancer diagnosis and drugs.

The market studied has been witnessing considerable growth, which is attributed to the increasing prevalence of cervical cancer among women, worldwide. According to the World Health Organization (WHO), more than 270,000 women die every year due to cervical cancer. The cervical cancer mortality rate is higher in developing countries, due to improper detection at early stages of the disease. With the rising adoption of cervical cancer diagnostic tests for the early detection of cervical cancer, the market is expected to grow.

Increasing awareness among the general population regarding the care, prevention, and treatment of cervical cancer, the rise in certain behaviors such as sex with multiple-partners and smoking, certain genetic factors, and weak immune system are all linked to the growth of the cervical cancer diagnostics and therapeutics market.

Awareness programs have helped in the growth of the market. For instance, Medicaid, the popular government insurance program, covers the screening for cervical cancers. Medicare, another widely used insurance, covers Pap test, pelvic exam, and clinical breast exam for cervical cancer screening, every two years. These programs were found to be responsible for the growth of the overall market.

Scope of the Report

Cervical cancer refers to a malignancy of cervical cells. More than 90% of cervical malignancies occur due to HPV infection (human papillomavirus), which can be diagnosed through smear screening. The most common types of cervical cell cancer are squamous cell malignancy and adenocarcinoma. Cervical cancer diagnostic tests are being widely used for the detection of precancerous or cancerous lesions in the cervix of females.

Key Market Trends

Pap Smear Test, the Largest Segment Under Diagnostic Test, is Expected to Grow During the Forecast Period

Pap smear test, the most effective tool for the diagnosis of HPV, was found to be the most revenue-generating segment. Factors, such as the increasing prevalence of HPV infection in women and the deficiency of the HPV vaccine, which does not cover all types of HPV infections, are promoting the growth of the market.

North America, which Holds the Largest Share in the Market, is Expected to Follow the Same Trend, Over the Forecast Period

North America is the largest market for cervical cancer diagnostics and therapeutics. The large market share is attributed to the high awareness about disease prevention among women in the region, as well as to the many initiatives launched to prevent cervical cancer, which has increased the reach of insurance coverage for cervical screening tests, especially for low-income women.

Asia-Pacific, the fastest growing market for cervical cancer diagnostic tests, attributes its growth to the increasing prevalence of cervical cancer in developing countries, including China, India, Malaysia, Japan, South Korea, and Australia.

Competitive Landscape

Intense competition was observed in the market for cervical cancer diagnostics and therapeutics, due to the presence of a large number of cervical cancer patients. Companies are currently focusing on developing advanced techniques for diagnosis, such as liquid-based cytology.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Favorable Government Initiatives Toward Cervical Cancer Prevention
    • 4.2.2 Growing Prevalence of Cervical Cancer
    • 4.2.3 Increasing Awareness Regarding Early Diagnosis
    • 4.2.4 Strong R&D from Key Players for Cervical Cancer Diagnosis and Drugs
  • 4.3 Market Restraints
    • 4.3.1 Economic Constraints in Many Countries to Adopt Regular Testing Procedures
    • 4.3.2 High Cost of Cancer Therapies
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Diagnostic Test
    • 5.1.1 Pap Smear Test
    • 5.1.2 HPV Test
    • 5.1.3 Colposcopy
    • 5.1.4 Biopsy and Endocervical Curettage
    • 5.1.5 Other Diagnostic Tests
  • 5.2 By Therapeutic
    • 5.2.1 Avastin (Bevacizumab)
    • 5.2.2 Blenoxane (Bleomycin)
    • 5.2.3 Hycamtin (Topotecan Hydrochloride)
    • 5.2.4 Gemcitabine-Cisplatin
    • 5.2.5 Vaccines
      • 5.2.5.1 Gardasil
      • 5.2.5.2 Cevarix
    • 5.2.6 Other Therapeutics
  • 5.3 By End User
    • 5.3.1 Hospitals
    • 5.3.2 Specilty Clinics
    • 5.3.3 Cancer and Radiation Therapy Centers
    • 5.3.4 Diagnostic Centers
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 US
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 UK
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East & Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East & Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Bristol-Meyrs Squibb Company
    • 6.1.3 GlaxoSmithKline PLC
    • 6.1.4 Merck & Co. Inc.
    • 6.1.5 Pfizer Inc.
    • 6.1.6 Qiagen NV
    • 6.1.7 Advaxis Inc.
    • 6.1.8 Becton, Dickinson and Company
    • 6.1.9 F. Hoffmann-La Roche Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top